Drugs / QL1604
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05649761 | May 2019 → Jul 2020 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05603039 | Jul 2021 → Dec 2023 | hepatocellular carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04864782 | Sep 2020 → Sep 2022 | cervical cancer | Qilu Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 2/3 | NCT04435652 | Jul 2020 → Apr 2022 | gastroesophageal adenocarcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06789796 Comparator | Feb 2025 → Mar 2028 expected | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1604 | “Cohort B will be QL1604 200 mg fixed dose q3w + bevacizumab safety dose” NCT05603039 ↗ |
| Action | Inhibit | “PD-1 Inhibitor (QL1604)” NCT04864782 ↗ |
| Modality | Monoclonal antibody | “a humanized anti-PD-1 monoclonal antibody” NCT05649761 ↗ |
| Route | Intravenous | “3mg/kg, D1,8,15,Q4w, IV infusion” NCT04435652 ↗ |